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Heme oxygenase-1 derived carbon monoxide
suppresses Aβ1–42 toxicity in astrocytes
Nishani T Hettiarachchi1, John P Boyle1, Mark L Dallas2, Moza M Al-Owais1, Jason L Scragg1 and Chris Peers*,1
Neurodegeneration in Alzheimer’s disease (AD) is extensively studied, and the involvement of astrocytes and other cell types in
this process has been described. However, the responses of astrocytes themselves to amyloid β peptides ((Aβ; the widely
accepted major toxic factor in AD) is less well understood. Here, we show that Aβ(1-42) is toxic to primary cultures of astrocytes.
Toxicity does not involve disruption of astrocyte Ca2+ homeostasis, but instead occurs via formation of the toxic reactive species,
peroxynitrite. Thus, Aβ(1-42) raises peroxynitrite levels in astrocytes, and Aβ(1-42) toxicity can be inhibited by antioxidants, or by
inhibition of nitric oxide (NO) formation (reactive oxygen species (ROS) and NO combine to form peroxynitrite), or by a scavenger
of peroxynitrite. Increased ROS levels observed following Aβ(1-42) application were derived from NADPH oxidase. Induction of
haem oxygenase-1 (HO-1) protected astrocytes from Aβ(1-42) toxicity, and this protective effect was mimicked by application of the
carbon monoxide (CO) releasing molecule CORM-2, suggesting HO-1 protection was attributable to its formation of CO. CO
suppressed the rise of NADPH oxidase-derived ROS caused by Aβ(1-42). Under hypoxic conditions (0.5% O2, 48 h) HO-1 was
induced in astrocytes and Aβ(1-42) toxicity was significantly reduced, an effect which was reversed by the specific HO-1 inhibitor,
QC-15. Our data suggest that Aβ(1-42) is toxic to astrocytes, but that induction of HO-1 affords protection against this toxicity due to
formation of CO. HO-1 induction, or CO donors, would appear to present attractive possible approaches to provide protection of
both neuronal and non-neuronal cell types from the degenerative effects of AD in the central nervous system.
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The progression of Alzheimer’s disease (AD), from early loss
of functional synapses1–3 to the loss of neurones through
apoptosis and other pathways4–7 has been described exten-
sively, yet remains to be fully understood. The association of
disease progression with increased levels of amyloid β peptide
(Aβ; predominantly the 1–42 form, Aβ1–42) is also well
established: this peptide is neurotoxic, and is also an
important constituent of disease-characterising plaques.8,9
Astrocytes are as numerous as neurons in the central
nervous system10 and their role in neurodegenerative
diseases has also been extensively explored.11–13 These
cells are diverse in structure and function, regulating CNS
homeostasis in general and shaping activity at individual
synapses.11,14,15 More recently there is a growing apprecia-
tion of the heterogeneity of astrocytes.16 In AD, and transgenic
murine models of AD, atrophy of astrocytes is widely reported,
and reactive astrocytes (in part defined as staining positively
for glial fibrillar acidic protein; GFAP) have long been
anatomically associated with plaques (reviewed in ref. 11).
Atrophic loss of morphology clearly undermines the ability of
astrocytes to regulate synaptic activity, and disrupts the
‘neurovascular unit’ in which astrocytes play a central role in
balancing local blood flow to neuronal activity.17,18
Numerous in vitro studies have also established that
astrocytes can, at least in part, mediate the neurotoxic effects
of Aβ. Thus, for example, extrasynaptic glutamate release
from astrocytes in response to Aβ exposure leads to synaptic
damage and loss.19 Evidence exists that suggests Aβ disrupts
astrocyte [Ca2+]i and by doing so activates reactive oxygen
species (ROS) production by NADPH oxidase (reviewed in
ref. 20). This increases lipid peroxidation in both astrocytes
and neurones, which in turn depletes glutathione (GSH) levels
in both cell types. Since neurones require delivery of GSH
precursors from astrocytes, they are preferentially susceptible
to continued oxidative stress and so die, whereas astrocytes
have a greater antioxidant capacity to survive. It should be
noted, however, that this model is not universally accepted,
and others have indicated that astrocytic Ca2+ signalling is not
disrupted by Aβ, at least over the same timecourse, and that
different downstream signalling pathways are evoked.21,22
Despite the extensive literature on the involvement of
astrocytes in the progression of neurodegeneration in AD,
information available concerning the molecular mechanisms
underlying responses of astrocytes themselves to Aβ is
relatively limited and appears seemingly contradictory in some
respects. Thus, for example, astrocyte viability has been
reported to be unaffected or even slightly potentiated following
exposure to sub-micromolar Aβ1-42 for 24 h.
23 By contrast,
others have shown that astrocytes are susceptible to micro-
molar Aβ− induced death over similar time periods.24 In the
present study, we demonstrate that cortical astrocytes can
undergo apoptotic death when exposed to sub-micromolar
levels of Aβ1-42, and that this occurs via formation of
peroxynitrite (ONOO–). Furthermore, we demonstrate a
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complex pattern of modulation of this process of Aβ toxicity by
the induction of the antioxidant enzyme haem oxygenase-1
(HO-1).
Results
Exposure of astrocytes to Aβ1-42 (10 nM-1 μM) for 24 h caused
a concentration-dependent loss of viability, as shown in
Figure 1a. This toxic effect of Aβ appeared selective, since
the reverse sequence peptide, Aβ42-1, was without effect over
the same concentration range (Figure 1a). In the presence of
the caspase-3 inhibitor Z-DEVD-FMK (10 μM) the toxic effects
of Aβ1–42 were partially reversed, suggesting the toxicity of
Aβ1–42 was at least partly due to the induction of apoptosis.
Since it has previously been suggested that amyloid
peptides disrupt [Ca2+]i in astrocytes, we next examined
whether [Ca2+]i was altered in astrocytes at the levelswe found
to be toxic. As shown by the examples in Figure 2a, and the
mean data of Figure 2b, exposure of astrocytes to 100 nM or
500 nM Aβ1–42 for 24 h caused a modest but significant
reduction in resting [Ca2+]i whereas 500 nM reverse peptide
(Aβ42-1) waswithout significant effect. Removal of extracellular
Ca2+ (replaced with 1 mM EGTA) caused a reversible fall of
[Ca2+]i in all cell groups examined, and basal [Ca
2+]i under
these conditions were similar across the 4 groups (Figure 2b,
middle). Restoration of extracellular Ca2+ caused a transient
overshoot of [Ca2+]i in control and reverse-peptide treated
astrocytes, and this was significantly suppressed in cells
exposed to Aβ1-42. This difference aside, our results are not
consistent with the idea that Aβ1–42 is toxic due to its ability to
raise [Ca2+]i as has previously been suggested.
20
ROS generation has often been associated with amyloid
toxicity.25,26 To investigate any potential role for ROS in
amyloid-mediated loss of astrocyte viability, we first examined
the effects of MnTMPyP, a superoxide dismutase mimetic. As
shown in Figure 3a, MnTMPyP significantly ameliorated the
toxic effects of Aβ1–42. However, treatment of cells with mito-
TEMPO, a mitochondria targeted antioxidant, was unable to
modify significantly the toxic effects of Aβ1–42, suggesting that
ROS were not derived from mitochondria (Figure 3b). Instead,
a significant reduction in the toxicity of Aβ1–42 was observed in
the presence of either apocyanin, a non-specific inhibitor of
NADPH oxidase (Figure 3c), or the NOX1/NOX4 inhibitor,
GKT13783127 (Figure 3d). These data are consistent with
NADPH oxidase as being at least partly responsible for the
production of toxic ROS following exposure to Aβ1–42.
It was noteworthy in the studies reported in Figures 2 and 3
that ROS inhibition could not fully reverse the toxic effects of
Aβ1–42, suggesting the involvement of other factors. Amyloid
peptides have long been known to increase nitric oxide (NO)
formation via induction of iNOS in astrocytes and
neurones.24,28–30 Increased formation of NO, in the presence
of elevated ROS levels, can lead to formation of the highly toxic
ROS, peroxynitrite (ONOO–). To explore a possible role for
ONOO– we first examined its effects on astrocyte viability.
ONOO– formation was monitored using 2-[6-(4′-amino)
phenoxy-3H-xanthen-3-on-9-yl]benzoic acid (APF) fluores-
cence. Exposure of cells to the NO donor S-nitrosopenacilla-
mine (SNAP; 200 μM) alone was without effect on APF
fluorescence (Figure 4a), but when applied with pyrogallol
(100 μM), which auto-oxidises to form superoxide, a clear rise
of APF fluorescence was apparent (Figures 4a–c). Figure 4b
illustrates two images of APF fluorescence, before and during
exposure to SNAP together with pyrogallol. Mean data are
plotted in Figure 4c, which also illustrates the ability of the
ONOO– scavenger FeTPPs (5,10,15,20-tetrakis-[4-sulfonato-
phenyl]-porphyrinato-iron[III]; 50 μM), which converts ONOO–
rapidly to nitrate,31 to reduce the SNAP / pyrogallol rise of
ONOO–. Figure 4d shows that ONOO– is highly toxic to
astrocytes: exposure to SNAP alone was without significant
effect on astrocyte viability, but together with pyrogallol it
caused a striking loss of cells. This effect was prevented by the
superoxide dismutase mimetic MnTMPyP (Figure 4d).
The data in Figure 4 show clearly that formation of ONOO–
in astrocytes is detectable, and is highly toxic. To investigate
whether Aβ1–42 can exert its toxic actions through the
formation of ONOO– we first examined its ability to increase
APF fluorescence. As exemplified in the images of Figure 5a
and themean data of Figure 5b, APF fluorescence was indeed
increased following a 24 h exposure to Aβ1–42. Consistent with
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Figure 1 Amyloid peptide Aβ1–42 is toxic to astrocytes in part via inducing
apoptosis. (a) Effect on cell viability of a 24 h exposure of astrocytes to Aβ1–42
(10–1000 nM, white bars) and the reverse peptide Aβ42-1 (grey bars) using the
mitochondrial activity-based MTT assay. Bars represent the mean± S.E.M. data of
cells from 4 repeats (each performed in duplicate) with cells from different
preparations. (b) as (a), except cells were exposed either to Aβ1–42 alone (10–
500 nM, white bars) or Aβ1–42 in the additional presence of 10 μM Z-DEVD-FMK, a
caspase-3 inhibitor (grey bars). Bars represent the mean± S.E.M. data of cells from
3 repeats (each performed in duplicate) with cells from different preparations.
Significant difference: ***Po0.001 effects of peptide alone compared to control, or
between amyloid peptide and reverse peptide (a), or effects of Z-DEVD-FMK at each
amyloid concentration, as indicated
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Figure 2 Aβ1–42 does not dramatically alter [Ca
2+]i in astrocytes. (a) Example microfluorimetric measurements of [Ca
2+]i in astrocytes under control conditions, or exposed to
Aβ1–42 or Aβ42-1 as indicated, for 24 h. Scale bars apply to all traces. In each case, for the period indicated by the grey area, extracellular Ca
2+ was replaced with 1mM EGTA. (b)
Mean±S.E.M. levels of [Ca2+]i measured in 8–9 recordings under normal conditions (left), during exposure to Ca
2+-free solution (containing 1 mM EGTA; middle) and following
replacement of Ca2+ in the perfusate (right). Significance: *Po0.05; **Po0.01; ***Po0.001 as compared with controls
Figure 3 Evidence for the involvement of NADPH oxidase-derived ROS in Aβ1–42 toxicity. (a) Effect on cell viability of a 24 h exposure of astrocytes to Aβ1–42 alone
(10–500 nM, white bars) or Aβ1–42 in the additional presence of 100 μMMnTMPyP (grey bars). Bars represent the mean± S.E.M. data of cells from 3 repeats (each performed in
duplicate) with cells from different passages. (b) as (a), except cells were either treated with Aβ1–42 alone (10–500 nM, white bars) or Aβ1–42 in the additional presence of 10 μM
Mito-TEMPO (grey bars). Bars represent the mean±S.E.M. data of cells from 3 repeats (each performed in duplicate). Significance: ***Po0.001 as compared with respective
controls, or between cells without drug versus MnTMPyP (a). NS, not significant. (c) Effect on cell viability of a 24 h exposure of astrocytes to Aβ1–42 alone (100–1000 nM, white
bars) or Aβ1–42 in the additional presence of 1 mM apocyanin (grey bars). Bars represent the mean± S.E.M. data of cells from 3 repeats (each performed in duplicate) with cells
from different preparations. (d) as (c), except cells were either treated with Aβ1–42 alone (100–1000 nM, white bars) or Aβ1–42 in the additional presence of 10 μM GKT137831
(grey bars). Bars represent the mean±S.E.M. data of cells from 2 repeats (each performed in duplicate) with cells from different preparations. Significance: **Po0.01;
***Po0.001 as compared either with respective controls, or between drug treatment or no treatment, as indicated
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the idea that ONOO– may contribute to its toxicity, we also
found that Aβ1–42 induced loss of astrocyte viability was
essentially completely prevented in the presence of L-NAME
to prevent NO formation (Figure 5c). Similarly, in the presence
of the ONOO– scavenger FeTPPS, Aβ1–42 was without
significant effect on astrocyte viability (Figure 5d. Together,
these findings suggest that Aβ1–42 is deleterious to astrocytes
due to stimulation of elevated levels of both ROS and NO,
which subsequently form ONOO .
We have previously shown that induction of HO-1 affords
protection in neurons against the toxicity of Aβ1–42.
32 To
investigate whether HO-1 was similarly protective in astro-
cytes, we first induced its expression by exposing astrocytes to
an HO-1 inducer, cobalt protoporphyrin IX (CoPPIX; 3 μM) for
24 h. As shown in Figure 6a such treatment caused a strong
induction of HO-1, and in CoPPIX-treated astrocytes, the toxic
effects of Aβ1–42 (added for the same 24 h exposure to
CoPPIX) were significantly attenuated (Figure 6b). Earlier
studies have shown that carbon monoxide (CO), a product of
HO-1-mediated haem degradation, can provide protection
against apoptosis33,34 and so we investigated such a role for
CO in astrocytes. As illustrated in Figure 6c, exposure of cells
to the CO donor CORM-2 (3–20 μM) caused a concentration-
dependent reversal of Aβ1–42 toxicity without significantly
affecting the viability of astrocytes not exposed to Aβ1–42. The
control compound iCORM (which does not release CO) was
unable to affect the toxicity of Aβ1–42. Neither CORM-2 nor
iCORM induced significant levels of HO-1 themselves
(Supplementary Figure 1). Similarly, L-NAME did not alter
HO-1 expression significantly (Supplementary Figure 1).
Biliverdin, another HO-1 product, was without effect on the
toxicity of Aβ1–42 (Supplementary Figure 2).
A previous study has reported that CO inhibits NADPH
oxidase in proliferating smooth muscle.35 Since NADPH
oxidase was a significant source of ROS mediating Aβ1–42
toxicity (Figure 3), we investigated whether CO inhibition of
NADPH oxidase activity accounted for its protective effects
against Aβ1–42 toxicity. To do this, we examinedROS formation
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Figure 4 Peroxynitrite is highly toxic to astrocytes. (a) Fluorescence images of astrocytes loaded with the ONOO– sensitive dye, 2-[6-(4′-amino) phenoxy-3H-xanthen-3-on-9-
yl]benzoic acid (APF). Cells were first treated with vehicle (DMSO; 1:1000) and then SNAP (200 μM) alone or together with pyrogallol (100 μM). (b) Example timecourses of the
changes in APF fluorescence seen in cells exposed to SNAP alone (10 μM) or SNAP together with pyrogallol (100 μM). (c) Mean±S.E.M. peak fluorescence detected in
astrocytes exposed to vehicle, SNAP (200 μM), SNAP together with pyrogallol (100 μM) or both agents together with the ONOO– scavenger FeTPPS (50 μM). **Po0.01 as
compared with control. (d) Effect on cell viability of a 24 h exposure of astrocytes to SNAP (200 μM), SNAP together with pyrogallol (100 μM) or both agents together with the
antioxidant MnTMPyP (100 μM). Each bar represents the mean±S.E.M. taken from between 4 and 8 observations. Significance; ***Po0.001 as compared with control
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using CellROX deep Red, a fluoroprobe which emits fluores-
cence upon oxidation. Representative images are shown in
Figure 7a, and quantified in Figure 7b. As compared with
untreated cells, those exposed to Aβ1–42 showed a significant
increase in ROS production (increased cytoplasmic fluores-
cence) and this was significantly reduced by the NOX1/NOX4
inhibitor, GKT137831 (10 μM). Fluorescence was also sig-
nificantly suppressed by 20 μM CORM-2 but not by iCORM.
Interestingly, CORM-2 alone caused a modest rise in
fluorescence, presumably because it is known to stimulate
ROS formation from mitochondria.36
HO-1 is induced by several forms of cellular stress,
prominent amongst which is hypoxia.37,38 We maintained
astrocytes in hypoxia (0.5% O2) for 48 h and found this
induced HO-1 strongly, as observed using both immunohis-
tochemistry (Figure 8a) and western blotting (Figure 8b).
Astrocytes maintained in hypoxia for a subsequent 24 h
exposure to Aβ1–42 were significantly more resistant to toxicity
than those maintained under control (normoxic) conditions
(Figure 8c). Hypoxic resistance to Aβ1–42 toxicity appeared to
be due specifically to HO-1 induction, since it was largely
prevented by application of the selective HO-1 inhibitor
QC-1539 (Figure 8c).
Discussion
The present study demonstrates that sub-micromolar levels of
Aβ1–42 have a significant impact on astrocyte viability over a
24 h period in comparison to a control peptide. Whilst these
findings at least superficially agree with some previous
studies,24 others have indicated that Aβ1–42 does not alter
astrocyte viability,23 but can disrupt [Ca2+]i
20. These latter
findings contrast with our observations both on viability
(Figure 1) and alterations in [Ca2+]i (Figure 2). At present we
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Figure 5 Aβ1-42toxicity involves peroxynitrite formation. (a) Separate fluorescence images of astrocytes loaded with the ONOO
– sensitive dye, 2-[6-(4′-amino) phenoxy-3H-
xanthen-3-on-9-yl]benzoic acid (APF). Cells were either untreated or exposed to 500 nM Aβ1-42 for 24 h. (b) Mean±S.E.M. (taken from 5-10 recordings) APF fluorescence
detected in astrocytes without treatment, or following a 24 h treatment with either 100–1000 nM Aβ1–42 or reverse peptide (500 nM), as indicated. *Po0.05; **Po0.01 as
compared with control. (c) Effect on cell viability of 24 h exposure of astrocytes to Aβ1–42 alone (100–1000 nM, white bars) or Aβ1–42 in the additional presence of 500 μM
L-NAME (grey bars). Bars represent the mean±S.E.M. data of cells from 6 repeats (each performed in duplicate) with cells from different preparations. Significance: ***Po0.001
as compared either with respective controls, or between drug treatment or no treatment, as indicated. (d) as (c), except that cells were exposed either to Aβ1–42 alone (100–
1000 nM, white bars) or Aβ1–42 in the additional presence of 50 μM FeTPPs (grey bars). Bars represent the mean±S.E.M. data of cells from 3 repeats. Significant difference:
***Po0.001 effects of peptide alone compared to control, or between amyloid peptide with or without FeTPPS at each amyloid concentration, as indicated
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cannot account for such different responses, but one likely
possibility is the peptide preparation used. Our studies have
employed peptides that were maintained for 24 h at 37 °C in
medium before being applied to cells. We have previously
shown that under these conditions cells are exposed to a
mixture of monomers, small globular assemblies and proto-
fibrils, as assessed by electron microscopy.32 By contrast,
elevations in astrocytic [Ca2+]i were observed following acute
application of 10–50 μM of Aβ1–42 which was prepared in
ultrapure water, reducing the likelihood of aggregation.40,41
Despite these reported differences, what is clear from this
study and others is that Aβ1–42 can elevate astrocytic ROS
levels. This is likely to be pathologically important, and
precedes amyloid-induced increases of ROS in neurons.42
ROS derived from mitochondria have been implicated in
ageing and associated with Ca2+ mobilisation in astrocytes.43
In the present study, NADPH oxidase(s) appear to be major
contributors to the increased ROS levels (see ref. 44 and
Figure 3). Although we have not explored the mechanism
underlying amyloid-mediated stimulation of NADPH oxidase
activity, it has previously been suggested that this occurs via
Ca2+-dependent activation of protein kinase Cβ.44,45 Whether
or not the same process underlies NADPH oxidase activation
as reported here is unclear, but it is noteworthy that no
elevation of [Ca2+]i was observed in the present study
(Figure 2).
Astrocytes respond to pro-inflammatory signals with the
release of toxic species, including ONOO– (see refs 46,47). It
has previously been reported that astrocytes are relatively
resistant to ONOO– toxicity when applied exogenously or
derived from iNOS.48,49 Indeed, although NO modulates
mitochondrial function in astrocytes, no overt toxicity has been
reported50 in agreement with this study (Figure 4d). However,
all three isoforms of nitric oxide synthase (NOS) are elevated
in AD,51,52 and Lipton and colleagues have produced a
number of studies which collectively provide compelling
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Figure 6 HO-1 induction protects astrocytes from Aβ1–42 toxicity via CO formation. (a) Left, western blot for HO-1 taken from control astrocytes and astrocytes exposed to
CoPPIX (3 μM) for 24 h, as indicated. β-actin was also probed to confirm approximately equal protein loading of lanes. Below, mean±S.E.M. (n= 3) relative densitometric
readings for control and CoPPIX-treated cells, as indicated. *Po0.05. Right, images of control and CoPPIX-treated cells, immunostained for HO-1. Scale bar applied to both
images. (b) Effect on cell viability of a 24 h exposure of astrocytes to Aβ1–42 alone (100 nM, white bar) or Aβ1–42 in the additional presence of 3 μMCoPPIX. Also shown is the lack
of effect of CoPPIX alone. Bars represent the mean±S.E.M. data of cells from 5 repeats (each performed in duplicate) with cells from different preparations. ***Po0.001. (c)
Effect on cell viability of a 24 h exposure of astrocytes to 100 nM Aβ1–42 in the absence (white bar) or presence (dark grey bars) of the CO donor CORM-2 (3–20 μM). The effects
of CORM-2 alone are also presented (light grey bars), along with the effects of 100 nM Aβ1–42 in the additional presence of the inactive form of CORM-2, iCORM (hatched bars).
Bars represent the mean±S.E.M. data of cells from 6 repeats (each performed in duplicate) with cells from different preparations. ***Po0.001
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evidence that much of the toxicity of amyloid peptides arises
due to stimulation of NO production.53–56 Aberrant, or
excessive nitrosylation of target proteins (that is, conversion
of cysteine –SH groups to –SNO groups) accounts for many of
these deleterious effects.30,55,56 However, amyloid peptides
have also been reported to increase ONOO– levels in vivo46,47
and this can also impact on protein function through nitration of
tyrosine residues.57 Indeed, Aβ1–42 has been reported to be a
target of nitration, which can result in increased peptide
aggregation.58 Given these reported differential sensitivities to
NO and NO-related ROS, we examined the involvement of
both NO and ONOO–. Consistent with previous studies our
data highlighted that NO alone does not mediate amyloid
toxicity. However, when added with a source of superoxide,
pyrogallol, a dramatic rise of ONOO– was observed, together
with a large reduction in cell viability (Figure 4). These effects
could be reversed by the ONOO– scavenger, FeTPPs, the
superoxide dismutase mimetic MnTMPyP, and also by
L-NAME-mediated inhibition of NO formation (Figures 3, 4
and 5). As we also demonstrated that Aβ1–42 could directly
raise ONOO– levels (Figure 5b), our data strongly suggest that
the toxic effects of Aβ1–42 on astrocytes are due to its ability to
promote both ROS and NO formation and hence increase
ONOO– levels.
The cytotoxic actions of ONOO– have been linked to
intracellular glutathione levels and also to haem oxygenase
activity.59 Induction of HO-1 in both neurons and astrocytes is
well known to be associated with AD60,61 although whether
this is beneficial, or contributes to disease progression, is
subject to debate: HO-1 induction specifically in glia has been
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Figure 7 Aβ1–42 increases ROS formation from NADPH oxidase. (a) Representative CellROX images of astrocytes under control conditions, or following a 24 h treatment with
100 nM Aβ1–42 alone, or together with GKT137831 (10 μM), or CORM-2 (20 μM) or iCORM (20 μM), as indicated. Bottom right image shows the effects of 20 μMCORM-2 alone.
All images also show DAPI (nuclear) staining. Scale bar applies to all images. (B) Mean±S.E.M. fluorescence determined under the conditions exemplified in a. Data taken from
10 regions of interest, measured in 3–5 images from 3 experimental repeats. Significance: ***Po0.001 as compared with control or compared with 100 nM Aβ1–42 treatment, as
indicated
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shown to be detrimental because of the oxidative activity of
iron liberated by haem degradation.62,63 However, we32 and
others64,65 have provided evidence that HO-1 induction is
protective. In the present study, HO-1 induction (either
chemically or via exposure to hypoxia) is clearly protective
against the toxic effects of Aβ1–42 and this protection is
attributable to the formation of CO. Similarly in neurons we
have shown that CO is protective against Aβ1–42 toxicity, but
significantly the underlying mechanisms are quite distinct: in
neurons, protection was attributable to inhibition of AMP-
dependent protein kinase activation.32 In contrast, the present
study demonstrates that CO provides protection via inhibition
of ROS production in astrocytes specifically by NADPH
oxidase. This correlates well with observations in smooth
muscle cells and macrophages, where HO-1 induction, and
resultant CO formation suppresses NADPH oxidase activity.35
This result is perhaps surprising, given that CO can itself
increase ROS formation (Figure 7), not from NADPH oxidase
but from mitochondria.36 Furthermore, CO can increase
formation of NO in various cell types (e.g. refs 66,67) and
can in some instances itself be damaging through formation of
ONOO–, as shown in neuroblastoma (SH-SY5Y) cells.66 The
source of ROS and / or the specific cell type is therefore likely
to be key to outcomes. Clearly, the present study shows that
CO is protective against Aβ1–42 toxicity in astrocytes, and this
is mediated through suppression of NADPH oxidase activity.
In summary, we have shown that sub-micromolar concen-
trations Aβ1–42 are toxic to astrocytes, due to the activation of
NADPH oxidase and subsequent elevation of ROS. In the
presence of tonic NOSactivity, ONOO– formation is increased.
Induction of HO-1 provides protection against Aβ(1–42) toxicity
primarily via inhibition of NADPH oxidase. Our findings
therefore further support the idea that HO-1 / CO is protective
in the central nervous system and reveals potential mechan-
isms by which neuroprotection may be enhanced in the face of
Aβ1–42 cellular toxicity of AD.
Materials and Methods
Astrocyte preparation. To obtain primary cultures of astrocytes, cerebral
cortices were removed from 5–7-day-old Wistar rats and placed in ice-cold
phosphate-buffered solution (PBS) containing no Ca2+ or Mg2+ (Gibco, Thermo-
Fisher, Paisley, UK). Meninges were removed and cortices were minced with a razor
blade and dispersed into the same buffer containing 0.25 mg/ml trypsin, at 37 °C for
15 min. Trypsin digestion was halted by the addition of an equal volume of buffer
supplemented with 16 μg/ml soy bean trypsin inhibitor (type I-S; Sigma Aldrich
(Gillingham, UK), UK), 0.5 μg/ml DNase I (EC 3.1.21.1 type II from bovine
pancreas; 125 kU/ml; Sigma Aldrich) and 0.3 mM MgSO4. The digested tissue was
then pelleted by centrifugation at 400 × g for 5 min and the supernatant decanted
before resuspending the cell pellet in 6.8 ml of buffer solution containing 100 μg/ml
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Figure 8 Hypoxia protects against Aβ1–42 toxicity via HO-1 induction. (a) Representative images of astrocytes immunostained for HO-1 under control conditions, or following
a 48 h exposure to hypoxia (0.5% O2) as indicated. Scale bar applies to both images. (b) Example of western blot showing induction of HO-1 by hypoxia (hyp., 48 h, 0.5% O2). Bar
graph plots mean± S.E.M. (n= 3) densitometry (relative to control (normoxia)) taken from blots. *Po0.05. (c) Effect on cell viability of a 24 h exposure of astrocytes to Aβ1–42
alone (100–1000 nM, white bars) or Aβ1–42 under hypoxic conditions in the absence (grey bars) or additional presence of 10 μM QC-15 (black bars). Bars represent the
mean± S.E.M. data of cells from 3 repeats (each performed in duplicate) with cells from different preparations. Significance: **Po0.01; ***Po0.001 as compared with control or
as compared between treatments, as indicated
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soy bean trypsin inhibitor, 0.5 μg/ml DNase I and 1.5 mM MgSO4. Tissue was
subsequently triturated gently with a 10 ml stripette (10 × ). The cloudy cell
suspension was pipetted into 120 ml of media. The culture medium consisted of
Eagle’s minimal essential medium supplemented with 10% foetal calf serum (v/v) and
1% (v/v) penicillin-streptomycin (Invitrogen, Paisley, UK). The cell suspension was
then aliquoted into 75 cm2 flasks. Cells were then kept in a humidified incubator at
37 °C (95% air, 5% CO2). Six hours after plating out the cell suspension, cells were
washed with fresh media to remove non-adhered cells and debris. This resulted in a
culture of astrocytes (GFAP positive) as previously described.68,69 Culture medium
was exchanged every 7 days and cells were grown in culture for up to 14 days.
MTT assays. Cell viability was investigated using MTT assays, as previously
described.32 This technique compares well with the ATP-based CellTiter-Glo
Luminescent Cell Viability Assay (Promega; SI Figure 3). Cells were cultured in
poly-lysine coated 96-well plates to ~ 50% confluence or greater. Experiments were
only carried out when all of the cell groups showed a similar confluency when
viewed under the microscope. The final volume of each well after any treatment was
kept at 100 μl. Cells were treated for 24 h with different concentrations of either
Aβ1–42 or the reverse peptide Aβ42-1 made up in serum-free media (SFM). The
media in the control cells was also replaced with SFM for 24 h to ensure that all
observations made were due to the application of Aβ rather than the result of serum
withdrawal. This was done for all the experiments involving Aβ application.
When applying the tricarbonyldichlororuthenium(II) dimer (CORM-2) for 24 h, cells
were treated twice a day (0930am and 1700 hours) to replenish the amount of CO in
the media. Some cells were treated in parallel identically with iCORM, the inactive,
control compound which cannot release CO. Following the 24 h treatments with Aβ
and CORM-2, the media was discarded and the cells washed gently with PBS. This
step was repeated to get rid of all the CORM-2 as it reacts with the MTT. Then
the PBS was replaced with 100 μl of fresh cell culture media in each well. For the
MnTMPyP experiments, the cells were pre-treated with MnTMPyP for 30 min prior to
applying Aβ1–42. For the L-NAME experiments, the cells were pre-treated with
L-NAME for 1 h prior to treating with Aβ1–42. Next, 11 μl of Thiazolyl Blue Tetrazolium
Bromide (5 mg/ml, MTT, Sigma) made up in sterile PBS was added to each well (10%
by volume) and the cells were incubated at 37 °C for 3 h. An equal volume (111 μl per
well) of solubilizing solution consisting of isopropanol and HCl (24 ml propan-1-ol/
isopropyl alcohol (Sigma) + 1 ml 1M HCl) was added to each well to lyse the cells and
the contents of each well was thoroughly mixed by pipetting. Absorbance was
measured at 570 nm and at 630 nm using a spectrophotometer. The experiments
were done in duplicate and repeated using cells from at least 3 different rat
preparations to ensure the reliability of results. All of the results were normalised to
untreated control cells and shown as a percentage change in cell viability compared
to the corresponding controls.
APF fluorescence. APF (2-[6-(4′-amino) phenoxy-3H-xanthen-3-on-9-yl]ben-
zoic acid) fluorescence was used to detect peroxynitrite (ONOO–) formation as
previously described.66 Cells were plated on to coverslips in 24-well plates and when
needed for experiments coverslips containing cells were incubated with 100 nM,
500 nM, 1 μM Aβ1–42 or 500 nM Aβ42-1 for 24 h. Following the 24 h treatments the
cells were incubated with 10 μM APF (Sigma Aldrich, UK) made up in HEPES
buffered saline and incubated in the dark for 1 h at 37 °C. Following the 1 h incubation
period, the coverslip was cut into fragments and one fragment was placed on a glass
slide containing 200 μl of HEPES- buffered saline with 10 μM APF. APF was used
due to its limited nonselective reactivity and resistance to light-induced auto-oxidation.
Oxidation causes bright green fluorescence with an excitation/emission maxima of
around 490/515 nm. Fluorescence increases when APF reacts with ONOO– and the
changes in fluorescence intensity were measured using a ZEISS (Oberkochen,
Germany) laser scanning confocal microscope (LSM 510). The change in
fluorescence was measured continuously for a total of 10 min. The fluophore was
excited at 488 nm (emission was at 510 nm) by sequential scanning with argon lasers
and the Zeiss AIM software was used to obtain the images. The same brightness,
contrast and gamma settings were used for each condition.
Western blotting. Cells used for immunoblotting were cultured in T75 flasks
and when confluent, were treated with Aβ1–42, Aβ42-1 or cobalt protoporphyrin
(CoPPIX) at the concentrations indicated in the Results for 24 h. For the hypoxic
experiments, cells were exposed to hypoxia (0.5% O2) for 48 h. Following the
treatments, cells were washed in PBS and then lysed in situ with 600 μl of
mammalian protein extraction reagent (M-PER, Pierce) containing complete
protease inhibitor tablets (Roche) for 30 min at room temperature. Protein levels in
the lysates were assessed using a BCA assay (Pierce). Cell proteins (typically
30 μg protein per lane) were separated on 12.5%, 0.75 mm thick polyacrylamide
SDS gels and electrophoretically transferred onto 0.2 μm PVDF membranes
(BioRad). The blots were blocked for 1 h with 10% milk protein in Tris-buffered
saline with 0.05% Tween (TBST) then probed with primary antibody raised against
HO-1 (1:200, rabbit polyclonal, Santa Cruz technologies or 1:1000 rabbit polyclonal,
GeneTEX) at 4 °C overnight. Next, membranes were washed with TBST for
3 × 10 min prior to incubating with anti-rabbit horse radish peroxidise-conjugated
secondary antibody (1:2000; Amersham Pharmacia Biotech, Buckinghamshire UK)
for 1 h at room temperature. Following this incubation, membranes were washed in
TBST for 3 × 10 min and bands visualised using an enhanced chemiluminescence
detection system and hyperfilm ECL (Merck, UK).
Immunofluorescence. Cells were cultured on poly-lysine coated glass
coverslips in 6-well plates at 450% confluence prior to treatment with Aβ1–42,
Aβ42-1 or cobalt protoporphyrin (CoPPIX) at the concentrations indicated in the
Results for 24 h, or prior to exposure to hypoxia (0.5% O2, 48 h). Following said
treatments, cells were immunostained for HO-1 expression. Briefly, media was
discarded and the cells were washed (3 × 5 min) with Dulbecco’s PBS. Cells were
then fixed with paraformaldehyde (4% in PBS) for 20 min, following which they were
permeabilized with PBS containing 0.22% Triton X100 supplemented with 10%
normal goat serum (NGS; Sigma). Following 3 × 5 min washes with Dulbecco’s PBS
containing 1% NGS, cells were then incubated overnight at 4 °C with the primary
antibody; rabbit polyclonal anti-HO-1 (1:100, Santa Cruz) in Dulbecco’s PBS
containing 1% NGS. The following day, cells were washed with Dulbecco’s PBS
containing 1% NGS (3 × 5 min). Antibody binding was visualised by incubating the
cells with a secondary antibody; Alexa Fluor-488 conjugated anti-rabbit IgG (1:1000,
Invitrogen), for 1 h in the dark. Post-incubation, and following 3 × 5 min washes with
Dulbecco’s PBS, coverslips were mounted on slides using VectashieldR mounting
media containing DAPI (Vector Laboratories, CA). The slides were then examined
using a Zeiss laser scanning confocal microscope (LSM 700).
Amyloid beta preparation. Aβ1–42 and Aβ42-1 (r-Peptides, Bogart USA)
were dissolved in DMEM (Gibco, Paisley, UK) to make up 100 μM stock solutions
and kept at − 20 °C. In order to form protofibrils prior to treating the cells, the Aβ
peptide was maintained at 37 °C for 24 h, as previously described.32
CellROX assay. Cells were cultured on poly-lysine coated glass coverslips in
6-well plates at ⩾ 50% confluence prior to treatment as described in the Results
section. Following treatment the media was removed, cells were washed with PBS
and 5 μM CellROX deep red regent (Molecular Probes, Life Technologies, Paisley,
UK) was applied for 30 min in the dark at 37 °C. Thereafter, cells were washed three
times with PBS and fixed with 10% buffered formaldehyde (Sigma) for 15 min. Cells
were then washed with PBS and the coverslips were mounted on slides using
Vectorshield mounting media containing DAPI (Vector Laboratories, Burlingame,
CA, USA). Slides were then examined using a Zeiss laser scanning confocal
microscope (LSM 700). Images for all the treatments on a particular day were taken
using identical settings. ImageJ software (NIH, Bethesda, USA) was used to
analyse the images. To do this, 10 regions of interest were obtained for each image
and 3–5 images each were taken for any given treatment on any given
experimental day.
Statistical analysis. Data are shown as mean±S.E.M. Statistical analysis
was carried out using one-way ANOVA followed by either the Dunnett’s or
Bonferroni post test, as appropriate. P-values ofo0.05 were considered significant.
CellROX results were analysed using a two-way ANOVA followed by a Bonferroni
post test. Po0.05 was considered to be significant.
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